Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06559033

Determine the Frequency of Variants in the GBA/PSAP Genes in Patients With MM or MGUS

No effective specific treatment is currently available for the management of Multiple Myeloma (MM) and Monoclonal Gammopathy of Undetermined Significance (MGUS). A better understanding of the pathophysiological mechanisms would make it possible to propose treatments specifically targeting the deregulated pathways.

Recruiting

Interested in participating?

Request Info

Key information

About this study

This study will characterise the links between rare diseases and complex, chronic diseases. Metabolism can be visualised as a complex network in which the various biomolecules represent metabolic nodes and are linked together by connections. The number of connections at a node influences the effect of that biomolecule on the metabolic network(s) as a whole. If a biomolecule has a large number of connections, altering a metabolic pathway involving it will have an effect that will spread throughout the network. On the other hand, metabolic pathways with a high flux have a major impact on the homeostasis of the network. Thus, alteration of such a metabolic pathway cannot be without consequence: a major alteration could induce a rare hereditary metabolic disease with an early-onset clinic, whereas an alteration with a moderate effect could participate in the pathogenesis of complex diseases, and may open up new therapeutic prospects for these tumour pathologies.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Major patients with multiple myeloma (MM) (defined by clonal proliferation of tumour plasma cells (>10%), presence of a monoclonal peak in serum or urine (excluding non-secretory myeloma) and organ involvement secondary to bone marrow invasion) or with MGUS (defined as bone marrow plasmacytosis of less than 10%, associated with a monoclonal protein of less than 30g/L and no clinical involvement).
  • Membership of a social security scheme
  • Adult having read and understood the information letter and signed the consent form

Exclusion criteria

  • Person deprived of liberty by an administrative or judicial decision or person placed under court protection / sub-guardianship or guardianship

Treatment and study plan

Evaluation of the presence and number of mutated alleles of the GBA/PSAP genes in patients with MM or MGUS

Biological

Estimation of the frequency of variants in the PSAP/GBA genes in patients with MM or MGUS, then comparison with a reference frequency from databases such as the Exome Aggregation Consortium, the Exome Sequencing Project, the 1000 Genomes Project and the dbSNP.

Other names: Evaluation of plasma concentrations of LGL1 in patients with MM or MGUS compared to controls, Evaluation of the % Reactivity of plasma immunoglobulins from patients with MM or MGUS towards LGL1

Primary outcomes

  1. Frequency of variants in the GBA/PSAP genes in patients with MM or MGUS

    Time frame: inclusion (one day)

    The main aim of the research is to determine the frequency of variants in the GBA/PSAP genes in patients with MM or MGUS.

Secondary outcomes

  1. Plasma concentrations of LGL1 in patients with MM or MGUS

    Time frame: inclusion (one day)

    Compare the plasma concentration of LGL1 in MM and MGUS patients versus control individuals

  2. Reactivity of monoclonal antibodies in MM and MGUS patients

    Time frame: inclusion (one day)

    Assess the % (proportion of patients with reactivity (% reactivity greater than 0) and those without (% reactivity equal to 0)) of reactivity of monoclonal antibodies from MM and MGUS patients to LGL1

Study contacts

Contact information is provided by the study sponsor or research team.

Abdellah AB TEBANI, Pr

CONTACT

[email protected]

02 32 88 81 24 ext. +33

Soumeya BEKRI, Pr

CONTACT

[email protected]

02 32 88 81 24 ext. +33

Sponsors and collaborators

Lead sponsor

University Hospital, Rouen

Other

Registry information

Official study title

Determine the Frequency of Variants in the GBA/PSAP Genes in Patients With Multiple Myeloma (MM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)

Acronym: GAMY

Important dates

Study start
2025
Primary completion
2026
Study completion
2027
First posted
Aug 19, 2024
Registry last updated
Jun 10, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.